Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 15 | 2023 | 404 | 3.300 |
Why?
|
| Renal Replacement Therapy | 6 | 2023 | 45 | 2.180 |
Why?
|
| Nephrology | 3 | 2021 | 18 | 1.490 |
Why?
|
| Renal Dialysis | 5 | 2023 | 193 | 1.410 |
Why?
|
| Critical Care | 2 | 2018 | 234 | 0.950 |
Why?
|
| Point-of-Care Systems | 2 | 2021 | 71 | 0.900 |
Why?
|
| Hepatorenal Syndrome | 5 | 2023 | 15 | 0.800 |
Why?
|
| Anticoagulants | 3 | 2020 | 270 | 0.720 |
Why?
|
| Kidney Failure, Chronic | 3 | 2017 | 232 | 0.690 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 127 | 0.650 |
Why?
|
| Hemofiltration | 1 | 2017 | 7 | 0.620 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 74 | 0.610 |
Why?
|
| Kidney | 2 | 2020 | 822 | 0.610 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 302 | 0.570 |
Why?
|
| Heparin | 1 | 2016 | 97 | 0.530 |
Why?
|
| Colloids | 1 | 2013 | 4 | 0.480 |
Why?
|
| Isotonic Solutions | 1 | 2013 | 21 | 0.480 |
Why?
|
| Critical Illness | 1 | 2017 | 344 | 0.480 |
Why?
|
| Albumins | 1 | 2013 | 39 | 0.480 |
Why?
|
| Fluid Therapy | 1 | 2013 | 87 | 0.460 |
Why?
|
| Mycobacterium Infections | 1 | 2011 | 12 | 0.420 |
Why?
|
| Mycobacterium | 1 | 2011 | 20 | 0.420 |
Why?
|
| Peritonitis | 1 | 2011 | 33 | 0.410 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 37 | 0.410 |
Why?
|
| Vasoconstrictor Agents | 3 | 2023 | 88 | 0.380 |
Why?
|
| Sepsis | 1 | 2013 | 250 | 0.380 |
Why?
|
| Angiotensinogen | 3 | 2013 | 12 | 0.340 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 3049 | 0.320 |
Why?
|
| Humans | 23 | 2023 | 54391 | 0.300 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 218 | 0.280 |
Why?
|
| Creatinine | 3 | 2018 | 169 | 0.220 |
Why?
|
| Intensive Care Units | 2 | 2014 | 232 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 825 | 0.170 |
Why?
|
| Ultrasonography | 1 | 2021 | 486 | 0.160 |
Why?
|
| Uremia | 1 | 2018 | 16 | 0.160 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2018 | 17 | 0.160 |
Why?
|
| Vancomycin | 1 | 2018 | 88 | 0.150 |
Why?
|
| Male | 10 | 2021 | 27347 | 0.140 |
Why?
|
| Citrates | 1 | 2016 | 11 | 0.140 |
Why?
|
| Echocardiography | 1 | 2019 | 392 | 0.140 |
Why?
|
| Prognosis | 5 | 2023 | 2126 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2017 | 98 | 0.140 |
Why?
|
| Research Design | 1 | 2018 | 375 | 0.140 |
Why?
|
| Arterial Pressure | 1 | 2015 | 50 | 0.130 |
Why?
|
| Proteomics | 1 | 2018 | 343 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 594 | 0.130 |
Why?
|
| Female | 11 | 2021 | 28471 | 0.130 |
Why?
|
| Empyema, Pleural | 1 | 2014 | 12 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2018 | 444 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2016 | 209 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2021 | 5612 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 489 | 0.120 |
Why?
|
| Renin | 1 | 2013 | 23 | 0.120 |
Why?
|
| Hypertension | 2 | 2019 | 565 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 231 | 0.110 |
Why?
|
| Renin-Angiotensin System | 1 | 2013 | 65 | 0.110 |
Why?
|
| Resuscitation | 1 | 2013 | 82 | 0.110 |
Why?
|
| Pneumonia | 1 | 2014 | 129 | 0.110 |
Why?
|
| Adult | 5 | 2020 | 14207 | 0.100 |
Why?
|
| Patient Selection | 1 | 2013 | 284 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 202 | 0.100 |
Why?
|
| Aged | 6 | 2019 | 10060 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 182 | 0.100 |
Why?
|
| Time Factors | 1 | 2017 | 3210 | 0.090 |
Why?
|
| Middle Aged | 7 | 2021 | 13082 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2013 | 1362 | 0.080 |
Why?
|
| Kidney Function Tests | 2 | 2019 | 59 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 1045 | 0.080 |
Why?
|
| End Stage Liver Disease | 2 | 2019 | 44 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1141 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 2606 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2017 | 466 | 0.060 |
Why?
|
| Disease Progression | 2 | 2017 | 915 | 0.050 |
Why?
|
| Lypressin | 1 | 2021 | 2 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 10 | 0.050 |
Why?
|
| Catheterization | 1 | 2021 | 108 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 25 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1082 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 736 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 79 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 74 | 0.040 |
Why?
|
| Colorimetry | 1 | 2018 | 12 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2019 | 291 | 0.040 |
Why?
|
| Manikins | 1 | 2018 | 40 | 0.040 |
Why?
|
| Cadaver | 1 | 2018 | 113 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1301 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2018 | 137 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 146 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 117 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 313 | 0.040 |
Why?
|
| Risk Factors | 2 | 2017 | 3937 | 0.040 |
Why?
|
| United States | 2 | 2021 | 5208 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 807 | 0.040 |
Why?
|
| Octreotide | 1 | 2015 | 13 | 0.030 |
Why?
|
| Midodrine | 1 | 2015 | 6 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 692 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2015 | 119 | 0.030 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2014 | 10 | 0.030 |
Why?
|
| Thoracostomy | 1 | 2014 | 13 | 0.030 |
Why?
|
| Thoracoscopy | 1 | 2014 | 20 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1083 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 2014 | 61 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1546 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 541 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 205 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 259 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 318 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2015 | 6459 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 476 | 0.030 |
Why?
|
| Risk | 1 | 2012 | 343 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 643 | 0.030 |
Why?
|
| Heart Failure | 1 | 2017 | 541 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2013 | 509 | 0.030 |
Why?
|
| Logistic Models | 1 | 2013 | 991 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2013 | 318 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2390 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 3431 | 0.020 |
Why?
|